• 제목/요약/키워드: PARG

검색결과 2건 처리시간 0.011초

ADP-Ribosylation: Activation, Recognition, and Removal

  • Li, Nan;Chen, Junjie
    • Molecules and Cells
    • /
    • 제37권1호
    • /
    • pp.9-16
    • /
    • 2014
  • ADP-ribosylation is a type of posttranslational modification catalyzed by members of the poly(ADP-ribose) (PAR) polymerase superfamily. ADP-ribosylation is initiated by PARPs, recognized by PAR binding proteins, and removed by PARG and other ADP-ribose hydrolases. These three groups of proteins work together to regulate the cellular and molecular response of PAR signaling, which is critical for a wide range of cellular and physiological functions.

Poly(ADP-ribose) protects vascular smooth muscle cells from oxidative DNA damage

  • Zhang, Chao;Luo, Tao;Cui, Shijun;Gu, Yongquan;Bian, Chunjing;Chen, Yibin;Yu, Xiaochun;Wang, Zhonggao
    • BMB Reports
    • /
    • 제48권6호
    • /
    • pp.354-359
    • /
    • 2015
  • Vascular smooth muscle cells (VSMCs) undergo death during atherosclerosis, a widespread cardiovascular disease. Recent studies suggest that oxidative damage occurs in VSMCs and induces atherosclerosis. Here, we analyzed oxidative damage repair in VSMCs and found that VSMCs are hypersensitive to oxidative damage. Further analysis showed that oxidative damage repair in VSMCs is suppressed by a low level of poly (ADP-ribosyl)ation (PARylation), a key post-translational modification in oxidative damage repair. The low level of PARylation is not caused by the lack of PARP-1, the major poly(ADP-ribose) polymerase activated by oxidative damage. Instead, the expression of poly(ADP-ribose) glycohydrolase, PARG, the enzyme hydrolyzing poly(ADP-ribose), is significantly higher in VSMCs than that in the control cells. Using PARG inhibitor to suppress PARG activity facilitates oxidative damage-induced PARylation as well as DNA damage repair. Thus, our study demonstrates a novel molecular mechanism for oxidative damage-induced VSMCs death. This study also identifies the use of PARG inhibitors as a potential treatment for atherosclerosis. [BMB Reports 2015; 48(6): 354-359]